{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T18:40:38Z","timestamp":1787942438446,"version":"build-2784847793"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,6,23]],"date-time":"2021-06-23T00:00:00Z","timestamp":1624406400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell. Infect. Microbiol."],"abstract":"<jats:p>\n                    Half maximal inhibitory concentrations (IC\n                    <jats:sub>50<\/jats:sub>\n                    ) to the experimental drug ATI-2307 and complete inhibition (IC\n                    <jats:sub>90<\/jats:sub>\n                    ) of the common clinically used antifungal drug amphotericin B were determined by microbroth dilution assay for a collection of 69 clinical isolates of\n                    <jats:italic>Cryptococcus neoformans<\/jats:italic>\n                    from Uganda that had high fluconazole IC\n                    <jats:sub>50<\/jats:sub>\n                    values. The majority of the clinical isolates tested had fluconazole IC\n                    <jats:sub>50<\/jats:sub>\n                    at or above 8 \u00b5g\/mL, but were susceptible to both amphotericin B (IC\n                    <jats:sub>90<\/jats:sub>\n                    \u22641 \u03bcg\/mL) and ATI-2307 (IC50 \u22640.0312 \u00b5g\/mL). No correlation between increased fluconazole minimum inhibitory concentration (MIC) and ATI-2307 or amphotericin B MIC was observed, suggesting that the cellular changes impacting fluconazole susceptibility did not impact the effectiveness of ATI-2307. Our results suggest that ATI-2307 is a promising new antifungal drug for use in the context of high fluconazole or other antifungal drug MICs and\/or in combination drug therapy regimens.\n                  <\/jats:p>","DOI":"10.3389\/fcimb.2021.695240","type":"journal-article","created":{"date-parts":[[2021,6,23]],"date-time":"2021-06-23T09:30:21Z","timestamp":1624440621000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":18,"title":["ATI-2307 Exhibits Equivalent Antifungal Activity in Cryptococcus neoformans Clinical Isolates With High and Low Fluconazole IC50"],"prefix":"10.3389","volume":"11","author":[{"given":"Elliot S.","family":"Gerlach","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Altamirano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Marina","family":"Yoder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony S.","family":"Luggya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Akampurira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David B.","family":"Meya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.","family":"Boulware","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Rhein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,6,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"143","DOI":"10.3201\/eid1001.020779","article-title":"Antifungal Susceptibilities of Cryptococcus neoformans","volume":"10","author":"Archibald","year":"2004","journal-title":"Emerg. Infect. Dis."},{"key":"B2","article-title":"Method for the Determination of Broth Dilution Minimum Inhibitory Concentrations of Antifungal Agents for Yeasts","volume-title":"EUCAST DEFINITIVE Document E.DEF 7.3.1","author":"Arendrup","year":"2017"},{"key":"B3","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1046\/j.1469-0691.2003.00571.x","article-title":"Cryptococcus neoformans var. neoformans Resistant to Fluconazole in An HIV-Negative Patient With Chronic Lymphocytic Leukemia","volume":"9","author":"Assing","year":"2003","journal-title":"Clin. Microbiol. Infect."},{"key":"B4","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1111\/myc.12747","article-title":"A Systematic Review of Fluconazole Resistance in Clinical Isolates of Cryptococcus Species","volume":"61","author":"Bongomin","year":"2018","journal-title":"Mycoses"},{"key":"B5","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1056\/NEJMoa1312884","article-title":"Timing of Antiretroviral Therapy After Diagnosis of Cryptococcal Meningitis","volume":"370","author":"Boulware","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1128\/aac.37.6.1383","article-title":"Susceptibilities of Serial Cryptococcus neoformans Isolates From Patients With Recurrent Cryptococcal Meningitis to Amphotericin B and Fluconazole","volume":"37","author":"Casadevall","year":"1993","journal-title":"Antimicrob. Agents Chemother."},{"key":"B7","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1186\/s12879-015-1023-8","article-title":"Increasing Trend of Fluconazole-Non-Susceptible Cryptococcus neoformans in Patients With Invasive Cryptococcosis: A 12-Year Longitudinal Study","volume":"15","author":"Chen","year":"2015","journal-title":"BMC Infect. Dis."},{"key":"B8","doi-asserted-by":"publisher","first-page":"ofz369","DOI":"10.1093\/ofid\/ofz369","article-title":"Minimum Inhibitory Concentration Distribution of Fluconazole Against Cryptococcus Species and the Fluconazole Exposure Prediction Model","volume":"6","author":"Chesdachai","year":"2019","journal-title":"Open Forum Infect. Dis."},{"key":"B9","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1128\/CMR.00046-13","article-title":"Tissue Penetration of Antifungal Agents","volume":"27","author":"Felton","year":"2014","journal-title":"Clin. Microbiol. Rev."},{"key":"B10","doi-asserted-by":"publisher","first-page":"7493","DOI":"10.1038\/s41598-019-43941-w","article-title":"Mortality Due to Cryptococcus neoformans and Cryptococcus gattii in Low-Income Settings: An Autopsy Study","volume":"9","author":"Hurtado","year":"2019","journal-title":"Sci. Rep."},{"key":"B11","doi-asserted-by":"publisher","first-page":"225.e1","DOI":"10.1016\/j.jcrc.2010.08.005","article-title":"The Value of Amphotericin B in the Treatment of Invasive Fungal Infections","volume":"26","author":"Klepser","year":"2011","journal-title":"J. Crit. Care"},{"key":"B12","doi-asserted-by":"publisher","first-page":"e438","DOI":"10.1111\/j.1439-0507.2010.01946.x","article-title":"Antifungal Susceptibilities of Cryptococcus neoformans Cerebrospinal Fluid Isolates From AIDS Patients in Kenya","volume":"54","author":"Mdodo","year":"2011","journal-title":"Mycoses"},{"key":"B13","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1086\/655143","article-title":"Cost-Effectiveness of Serum Cryptococcal Antigen Screening to Prevent Deaths Among HIV-infected Persons With a CD4+ Cell Count < or = 100 Cells\/Microl Who Start HIV Therapy in Resource-Limited Settings","volume":"51","author":"Meya","year":"2010","journal-title":"Clin. Infect. Dis."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1128\/aac.01159-07","article-title":"In Vitro and In Vivo Antifungal Activities of T-2307, A Novel Arylamidine","volume":"52","author":"Mitsuyama","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1056\/NEJMoa1710922","article-title":"Antifungal Combinations for Treatment of Cryptococcal Meningitis in Africa","volume":"378","author":"Molloy","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"e0008137","DOI":"10.1371\/journal.pntd.0008137","article-title":"Decreasing Fluconazole Susceptibility of Clinical South African Cryptococcus neoformans Isolates Over a Decade","volume":"14","author":"Naicker","year":"2020","journal-title":"PloS Negl. Trop. Dis."},{"key":"B17","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1097\/qai.0000000000001669","article-title":"A Prospective Evaluation of a Multisite Cryptococcal Screening and Treatment Program in HIV Clinics in Uganda","volume":"78","author":"Nalintya","year":"2018","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"B18","doi-asserted-by":"publisher","first-page":"4831","DOI":"10.1128\/iai.71.9.4831-4841.2003","article-title":"Sexual Cycle of Cryptococcus neoformans var. grubii and Virulence of Congenic a and \u03b1-Isolates","volume":"71","author":"Nielsen","year":"2003","journal-title":"Infect. Immun."},{"key":"B19","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1093\/mmy\/myw089","article-title":"Activity of VT-1129 Against Cryptococcus neoformans Clinical Isolates With High Fluconazole MICs","volume":"55","author":"Nielsen","year":"2017","journal-title":"Med. Mycol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1093\/jac\/dkx020","article-title":"In Vitro and In Vivo Antifungal Activities of T-2307, A Novel Arylamidine, Against Cryptococcus gattii: An Emerging Fungal Pathogen","volume":"72","author":"Nishikawa","year":"2017","journal-title":"J.\u00a0Antimicrob. Chemother."},{"key":"B21","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1097\/QAD.0b013e328322ffac","article-title":"Estimation of the Current Global Burden of Cryptococcal Meningitis Among Persons Living With HIV\/AIDS","volume":"23","author":"Park","year":"2009","journal-title":"AIDS"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1086\/344058","article-title":"Antifungal Resistance in Pathogenic Fungi","volume":"35","author":"Perea","year":"2002","journal-title":"Clin. Infect. Dis."},{"key":"B23","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.diagmicrobio.2011.07.007","article-title":"Wild-Type MIC Distributions and Epidemiologic Cutoff Values for Fluconazole, Posaconazole, and Voriconazole When Testing Cryptococcus neoformans as Determined by the CLSI Broth Microdilution Method","volume":"71","author":"Pfaller","year":"2011","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"B24","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/s0732-8893(98)00095-9","article-title":"Molecular Epidemiology and Antifungal Susceptibility of Cryptococcus neoformans Isolates From Ugandan AIDS Patients","volume":"32","author":"Pfaller","year":"1998","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"B25","doi-asserted-by":"publisher","first-page":"673","DOI":"10.2147\/idr.s235473","article-title":"Cryptococcus neoformans\/gattii Species Complexes From Pre-HIV Pandemic Era Contain Unusually High Rate of Non-Wild-Type Isolates for Amphotericin B","volume":"13","author":"Pharkjaksu","year":"2020","journal-title":"Infect. Drug Resist."},{"key":"B26","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1016\/S1473-3099(17)30243-8","article-title":"Global Burden of Disease of HIV-Associated Cryptococcal Meningitis: An Updated Analysis","volume":"17","author":"Rajasingham","year":"2017","journal-title":"Lancet Infect. Dis."},{"key":"B27","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/s1473-3099(19)30127-6","article-title":"Adjunctive Sertraline for HIV-Associated Cryptococcal Meningitis: A Randomised, Placebo-Controlled, Double-Blind Phase 3 Trial","volume":"19","author":"Rhein","year":"2019","journal-title":"Lancet Infect. Dis."},{"key":"B28","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/s1473-3099(16)00074-8","article-title":"Efficacy of Adjunctive Sertraline for the Treatment of HIV-Associated Cryptococcal Meningitis: An Open-Label Dose-Ranging Study","volume":"16","author":"Rhein","year":"2016","journal-title":"Lancet Infect. Dis."},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a019703","article-title":"Antifungal Drug Development: Challenges, Unmet Clinical Needs, and New Approaches","volume":"4","author":"Roemer","year":"2014","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"5892","DOI":"10.1128\/aac.05954-11","article-title":"T-2307 Causes Collapse of Mitochondrial Membrane Potential in Yeast","volume":"56","author":"Shibata","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"B31","doi-asserted-by":"publisher","first-page":"7197","DOI":"10.1128\/aac.01299-15","article-title":"Increased Antifungal Drug Resistance in Clinical Isolates of Cryptococcus neoformans in Uganda","volume":"59","author":"Smith","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"B32","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1517\/17425255.2014.883379","article-title":"Clinically Relevant Drug-Drug Interactions Between Antiretrovirals and Antifungals","volume":"10","author":"Vadlapatla","year":"2014","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/s1473-3099(09)70265-8","article-title":"Azole Resistance in Aspergillus fumigatus: A Side-Effect of Environmental Fungicide Use","volume":"9","author":"Verweij","year":"2009","journal-title":"Lancet Infect. Dis."},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00374-19","article-title":"The Novel Arylamidine T-2307 Selectively Disrupts Yeast Mitochondrial Function by Inhibiting Respiratory Chain Complexes","volume":"63","author":"Yamashita","year":"2019","journal-title":"Antimicrob. Agents Chemother."}],"container-title":["Frontiers in Cellular and Infection Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2021.695240\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,23]],"date-time":"2021-06-23T09:30:23Z","timestamp":1624440623000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2021.695240\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,23]]},"references-count":34,"alternative-id":["10.3389\/fcimb.2021.695240"],"URL":"https:\/\/doi.org\/10.3389\/fcimb.2021.695240","relation":{},"ISSN":["2235-2988"],"issn-type":[{"value":"2235-2988","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,23]]},"article-number":"695240"}}